0001140361-23-036319.txt : 20230726 0001140361-23-036319.hdr.sgml : 20230726 20230726213232 ACCESSION NUMBER: 0001140361-23-036319 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230719 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Centea Scott CENTRAL INDEX KEY: 0001823973 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 231115081 MAIL ADDRESS: STREET 1: C/O ANGIODYNAMICS, INC. STREET 2: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 4 1 form4.xml X0508 4 2023-07-19 0001275187 ANGIODYNAMICS INC ANGO 0001823973 Centea Scott 14 PLAZA DRIVE LATHAM NY 12110 true SVP/GM, VIT false Common Stock 2023-07-19 4 M 0 3415 0 A 61543 D Common Stock 2023-07-19 4 F 0 1230 8.92 D 60313 D Performance Right 2023-07-19 4 M 0 11782 0 D Common Stock 11782 0 D This acquisition of 3,415 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020. The exempt disposition of 1,230 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020. On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. /s/ Stephen A. Trowbridge, Attorney in Fact 2023-07-26